Literature DB >> 16353212

Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes.

David Victorson1, Mehul Soni, David Cella.   

Abstract

BACKGROUND: The primary aim of the current study was to determine whether radiographic tumor response is associated with patient-reported outcomes such as symptom response or health-related quality of life.
METHODS: A metaanalysis was conducted of 21 available studies from 1995-2003 that provided data sufficient for examining the association between tumor response and patient-reported outcomes, including symptom response and health-related quality of life. A second aim was to examine the influence of possible moderating study variables on effect size variation.
RESULTS: As hypothesized, patient-reported outcome improvement rates were most frequently associated with patients classified as a complete or partial response (CR/PR), followed by those with stable disease (SD) and progressive disease (PD). Moderate effect sizes were observed between the CR/PR and SD (effect size of 0.35) and CR/PR and PD categories (effect size of 0.43). A weak effect size was found between SD and PD (effect size of 0.16), raising concern over the meaningfulness of the SD category. No significant correlations were found between effect size and patient or study characteristics. Significant associations existed between treatment duration and age, study duration, survival, and symptom response rates, especially among PD patients.
CONCLUSION: Despite significant study-to-study heterogeneity, an important association exists in the correlation between tumor response and formal measures of change in patient-reported outcomes. A better understanding of this relation would be enhanced if future reports included estimates of effect size in patient-reported outcome change by tumor response category. Practical implications, limitations, and directions for future research are provided. Copyright (c) 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16353212     DOI: 10.1002/cncr.21637

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

Review 2.  Patient-reported outcomes as end points and outcome indicators in solid tumours.

Authors:  Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella
Journal:  Nat Rev Clin Oncol       Date:  2015-03-10       Impact factor: 66.675

Review 3.  Innovations in research and clinical care using patient-generated health data.

Authors:  Heather S L Jim; Aasha I Hoogland; Naomi C Brownstein; Anna Barata; Adam P Dicker; Hans Knoop; Brian D Gonzalez; Randa Perkins; Dana Rollison; Scott M Gilbert; Ronica Nanda; Anders Berglund; Ross Mitchell; Peter A S Johnstone
Journal:  CA Cancer J Clin       Date:  2020-04-20       Impact factor: 508.702

4.  Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.

Authors:  Jennifer L Beaumont; Zeeshan Butt; Jeanfrancois Baladi; Robert J Motzer; Tomas Haas; Norbert Hollaender; Andrea Kay; David Cella
Journal:  Oncologist       Date:  2011-04-01

5.  A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

Authors:  Deepa Rao; Zeeshan Butt; Sarah Rosenbloom; Don Robinson; Jamie Von Roenn; Timothy M Kuzel; David Cella
Journal:  J Pain Symptom Manage       Date:  2009-04-08       Impact factor: 3.612

6.  Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.

Authors:  Lynne I Wagner; Don Robinson; Matthias Weiss; Michael Katz; Phillip Greipp; Rafael Fonseca; David Cella
Journal:  J Pain Symptom Manage       Date:  2012-05-09       Impact factor: 3.612

7.  Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

Authors:  Lijie He; Yuee Teng; Bo Jin; Mingfang Zhao; Ping Yu; Xuejun Hu; Jingdong Zhang; Songbai Li; Yaling Gao; Yunpeng Liu
Journal:  BMC Cancer       Date:  2010-12-14       Impact factor: 4.430

8.  Oncology patient-reported claims: maximising the chance for success.

Authors:  H Kitchen; D Rofail; M Caron; M-P Emery
Journal:  Ecancermedicalscience       Date:  2011-05-09

9.  Cancer symptom response as an oncology clinical trial end point.

Authors:  Laura C Bouchard; Neil Aaronson; Kathleen Gondek; David Cella
Journal:  Expert Rev Qual Life Cancer Care       Date:  2018-06-07

10.  Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index.

Authors:  Gale Harding; David Cella; Don Robinson; Parthiv J Mahadevia; Jason Clark; Dennis A Revicki
Journal:  Health Qual Life Outcomes       Date:  2007-06-14       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.